CDT Equity Seeks Shareholder Approval for Catastrophic Dilution: 12.1M Pre-Funded Warrant Shares and Amended Toxic Note Terms
CDT sits 30% above its 52-week low of $2.53 on light trading volume (0.1× avg).
Summary
CDT Equity's definitive proxy seeks approval for up to 12.1 million shares from pre-funded warrants and reveals amended, more toxic terms on a $2.5M convertible note — extreme dilution for a company with only 786K shares outstanding and a going-concern warning.
Key Events · Corporate Governance and Compliance · CDT
-
12.1M Pre-Funded Warrant Shares Up for Vote
Proposal 5 asks shareholders to approve the issuance of up to 12,131,770 shares upon exercise of pre-funded warrants issued to Sarborg stockholders — over 15 times the current 786,716 shares outstanding, representing potential dilution exceeding 1,500%.
-
Amended J.J. Astor Note Terms Worsen
Proposal 4 reveals the convertible note principal has increased to $2,536,650, an additional 37,500 warrants were issued, and the conversion price is now 70% of the lowest VWAP over 20 days with a floor that resets to 20% of the lowest VWAP every six months — classic toxic financing features.
-
Cash Crisis and Going Concern Backdrop
The company had only $97,000 in cash as of its last 10-Q and a going-concern warning. These proposals are essential to fund operations but will massively dilute existing shareholders.
-
Meeting Set for August 28, 2026
The virtual annual meeting is scheduled for August 28, 2026, with a record date of August 3, 2026. Shareholders will vote on all proposals, including the reverse split authorization and the dilutive issuances.
Analysis · CDT · Life Sciences
CDT Equity's definitive proxy asks shareholders to approve the issuance of up to 12.1 million shares upon exercise of pre-funded warrants — a number that dwarfs the current 786,716 shares outstanding, representing potential dilution of over 1,500%. The filing also reveals that the J.J. Astor convertible note has been amended to include even more punitive terms: the total principal balance has grown to $2.5 million, an additional 37,500 warrants were issued, and the conversion price formula now uses 70% of the lowest VWAP over 20 days with a floor that resets downward every six months. These are classic death-spiral features that could decimate existing shareholders. The company is already in a cash crisis with a going-concern warning, and this proxy is a desperate plea to enable the massive share issuance needed to keep the lights on — but at a catastrophic cost to current investors.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $3.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $2.53 to $3,800.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.